Purpose. In this study, we prepared GapC 1-150 -IsdB 126-361 -TRAP (GIT) proteins plus heat-labile enterotoxin B (LTB) as an intra-molecular adjuvant, together with CpG to further enhance its immunogenicity.
INTRODUCTION
Staphylococcus aureus and streptococcal species are the most common opportunistic pathogens causing a broad spectrum of diseases, including superficial skin lesions, pneumonia, endocarditis, osteomyelitis in humans and mastitis in cattle [1] [2] [3] [4] . Because antibiotics are often used in clinical infection treatment, many multidrugresistant S. aureus and streptococcal species are emerging in many countries and regions [5] [6] [7] . Therefore, the development of an effective multi-subunit vaccine would be a promising strategy to prevent S. aureus and streptococcal species infection [8] . However, to date, no licensed prophylactic or therapeutic vaccines are available to protect humans and animals from S. aureus and streptococcal infection.
S. aureus and streptococcal species exhibit similarly invasive behaviours and generate dozens of virulence molecules that are anchored on their surface or secreted to extracellular space [9] [10] [11] , which helps them adapt to a variety of host niches and establish diverse infections. It is believed that immunization with a combination of multiple protective antigens from them may be a novel and effective strategy to prevent their infection [12, 13] .
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an essential housekeeping enzyme of bacteria, is associated with virulence and adherence in Streptococcus and S. aureus [14, 15] . Current research has shown that only one protein, glyceraldehyde-3-phosphate dehydrogenase-C (GapC), shows GAPDH activity in streptococci [16] . S. aureus contains glyceraldehyde-3-phosphate dehydrogenase-B (GapB) and GapC, performing the GAPDH function [17] . It was reported that gapc was highly conserved between Streptococcus and S. aureus and can induce protective immune responses in mice, indicating the cross-imminoprotective potential of GAPDHs in different pathogenic bacteria [18] . Our previous results showed that the survival rates of mice immunized with GapC 1-150 were similar to those for those immunized with full-length GapC [8] . This work indicated that GapC might replace full-length GapC on immunogenicity. In addition, a truncation form of iron-regulated surface determinant B (IsdB 126-361 ) combined with target of RNAIII-activating protein (TRAP) from S. aureus can enhance GapC-induced immunoprotective effects against Streptococcus and S. aureus [19] . Moreover, our previous results indicated that GIT protein, composed of GapC 1-150 from Streptococcus, IsdB 126-361 and full-length TRAP from S. aureus, can induce cross-immunoprotective responses in mice challenged by Streptococcus and S. aureus [8] , but the GIT immunogenicity still needed to be further enhanced to effectively defend Streptococcus and S. aureus infection.
The heat-labile enterotoxin B (LTB) subunit from enterotoxigenic Escherichia coli can, as an immune-modulatory molecule, induce the activation of B cells [20] and antigenpresenting cells through binding to its cell surface receptor, GM1-ganglioside [21] . Several studies have shown that the cytosine preceding the guanosine (CpG) oligodeoxynucleotides (ODN) adjuvant as short synthetic cDNA consisting of unmethylated CG dinucleotides, which are Toll-like receptor 9 (TLR9) ligands, can activate B cells and dendritic cells and induce Th1-mediated immune responses [22, 23] . Therefore, we postulated that the combination of LTB and CpG may exert a synergistic effect to stimulate the cellmediated immune response and the humoral immune response.
In this study, we aimed to prepare LTB-GIT protein, LTB as an intra-molecular adjuvant, and then LTB-GIT plus CpG as a vaccine candidate, in order to increase the protective immune response of GIT against S. aureus and Streptococcus infection.
METHODS
Animals and bacterial strains SPF female BALB/c (6-8 weeks of age) mice were purchased from the Experimental Animal Center, Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences (Harbin, People's Republic of China). S. aureus strain Newman, Streptococcus dysgalactiae strain LS0312, enterotoxigenic E. coli (ETEC) strain K88 and E. coli strain BL21 were stored in our laboratory. The S. aureus strain Newman and S. dysgalactiae were cultured in tryptic soy broth at 37 C overnight. ETEC strain K88 and E. coli strain BL21 were cultured in Luria-Bertani broth at 37 C overnight.
Construction of recombinant plasmids
The gene ltb, from which the signal peptide sequence was deleted, was amplified from the genomic DNA of ETEC strain K88 by PCR with forward primer 5¢-TATGTCGACAAGC TCCCCAGTCTATTACAGAACT-3¢ (Sal I site underlined) and reverse primer 5¢-GCTACCTCCTCCACTTCCGCC TCCGTTTTCCATACTGATTG-CCGC-3¢ (linker sequence underlined). The PCR conditions were as follows: denatur- Protein expression, purification and Western blot analysis The pET-32 a (+)-ltb-git recombinant plasmid was transformed into E. coli strain BL21, which was cultured in LB broth with 50 mg ml À1 ampicillin at 37 C. When the OD 600nm value reached 0.4, IPTG was added into LB broth at the final concentration of 1 mMol to induce the Histagged LTB-GIT expression.
For protein detection and purification, the recombinant bacteria were collected at 4 C by centrifugation, resuspended in PBS and sonicated for 10 min. The supernatant was harvested and stored at À20
C. The LTB-GIT proteins were purified by the nickel-nitrilotriacetic acid resin affinity chromatography kit (QIAGEN), according to the manufacturer's instructions. The purified proteins were verified by SDS-PAGE and Western blot. For Western blot, an anti-His tag antibody (Sigma) was used as the primary antibody and HRP-conjugated goat anti-mouse IgG antibody (Sigma) was used as the secondary antibody.
Immune activity of recombinant proteins Initially, endotoxin from LTB-GIT preparations was removed by Triton X-114 (Sigma) according to manufacturer's recommendations, and then the endotoxin activities of the LTB-GIT preparations were assessed using the Limulus amebocyte lysate (LAL) assay as previously described [24] . Finally, an ELISA assay was used to monitor the immune activity of recombinant proteins. Briefly, BSA, LTB, GIT and LTB-GIT were separately coated at a concentration of 10 µg ml
À1
. BSA was used as negative control group, LTB and GIT were used as a positive control group and LTB-GIT was used as an experimental group. After blocking with 3 % BSA, serum from mice immunized with LTB or GIT at 1 : 1000 dilution was added into a 96-well ELISA plate and incubated for 2 h at room temperature. Then, after washing, HRP-conjugated goat anti-mice IgG mAbs were incubated for 1 h at room temperature. After washing, TMB (3, 3¢, 5, 5¢-tetramethylbenzidine) solution was added as a substrate and 2 N sulfuric acid ended this reaction. Finally, optical densities (OD 450nm ) were detected and analysed with an automated ELISA plate reader. 
Immunization of mice
After obtaining LTB-GIT proteins, we next determined their immunogenicity. We divided 150 healthy BALB/c mice (6-8 weeks of age) into 5 groups of 30 animals each, which contained PBS, GIT, GIT plus CpG ODN, the motif of which, containing an unmethylated cytosine preceding the guanosine (5¢-TCCATGACGTTCCTGACGTT-3¢), was synthesized [Sangon Biotech (Shanghai) Co., Ltd, People's Republic of China], LTB-GIT and LTB-GIT plus CpG ODN groups, respectively. Each mouse was injected intramuscularly thrice with 100 µl of the emulsion containing 100 µg of protein treated with Triton X-114 alone or with the addition of 10 µg CpG ODN, with PBS as a control. Immunization was performed on days 0, 14 and 21, respectively. All of the animals were housed in a special pathogenfree environment.
Intracellular cytokine staining (ICS)
Antigen-specific CD4 + T cell responses were evaluated by ICS after vaccination. To assess the intracellular cytokines of CD4 + T cells, 14 days after the second immunization mice splenocytes were isolated and cultured for 4 h at 37 C in 1640 medium supplemented with 10 % foetal bovine serum (FBS), either alone (unstimulated) or with the GIT proteins (5 µg ml
À1
) in the presence of monensin (BD Biosciences), which inhibits cytokine secretion [25] . After stimulation, the splenocytes were stained with an FITC-labelled anti-mouse CD4 monoclonal antibody (BD Bioscience) for 30 min at 4 C. The cells were washed with PBS-T (PBS with 0.05 % (v/ v) Tween 20) three times, followed by permeabilization with Cytofix/Cytoperm (BD Bioscience) for 20 min at 4 C. The cells were then stained with a PE-Cy7-labelled anti-mouse IFN-g or an APC-labelled anti-mouse IL-2, IL-4 and IL-10 antibody (BD Bioscience). Finally, the 1Â10 4 labelled cells were used for flow cytometry analysis. The unstimulated T cells counts were used as background controls and subtracted when plotting the data. The responses were considered to be positive when the percentage of total cytokine-producing cells was at least twice that of the background [26] .
IgG detection by ELISA Seven days after the last immunization, IgG antibodies were detected in sera from immunized mice by ELISA as described previously [27] . Briefly, GIT proteins were used to coat the 96-well plates at a concentration of 10 µg ml À1 and incubated overnight at 4 C. After being washed three times with PBS-T, the plates were blocked with 3 % BSA for 2 h at 4 C, and then a twofold serial dilution of samples was added into the wells and incubated for 2 h at room temperature. After washing with PBST, HRP-conjugated goat antimouse IgG mAbs were added and incubated for 1 h at room temperature. After washing, TMB solution was incubated with the plate for 15 min. To stop the reaction, 2 N sulfuric acid was added and the OD 450nm was measured on an automated ELISA plate reader.
Challenge assay
To evaluate the protective immune function of LTB-GIT proteins plus CpG, the challenge assay was performed. Briefly, 7 days after the last immunization, 20 mice from each vaccinated group were challenged by intraperitoneal injection with exponential-phase bacterial culture. Ten of the mice were infected with lethal doses of 2Â10 9 c.f.u. of S. dysgalactiae strain LS0312 and the others were infected with lethal doses of 1Â10 9 c.f.u. of S. aureus strain Newman. The health condition of the mice was monitored and recorded every day after infection. Finally, the survival rate of mice from each group was determined after 14 days.
Statistical analysis
All statistical analyses were performed using an unpaired Student's t-test and SPSS 13.0 software. The data were presented as the means plus standard deviations from three independent experiments. P-values <0.05 were considered to be statisitically significant. 
RESULTS

Confirmation of LTB-GIT expression and immunogenicity
To obtain recombinant ltb-git plasmids, the ltb and git fragments were amplified from genomic DNA of ETEC and pET-32a(+)-git, respectively, and a nucleotide sequence encoding a GGGSGGGS linker was introduced between ltb and git fragments to maintain the native conformation of LTB-GIT protein. The about 2100 bp ltb-git fusion gene was obtained by chimaeric PCR and inserted into pET-32a (+) vector (Fig. 1a) . Both the enzyme digestion and sequence analysis showed that the recombinant plasmids pET-32a(+)-ltb-git were correctly constructed (Fig. 1b) . Finally, SDS-PAGE results indicated that 96.3 kDa fusion proteins were expressed and subsequently purified (Fig. 1c) , and Western blot results also confirmed that His-tagged LTB-GIT proteins were successfully expressed (Fig. 1d ).
As shown in Fig. 2a , endotoxin activities in LTB-GIT preparations after treatment using Triton X-114 were vastly decreased compared to before treatment, which indicated that endotoxin was removed from the protein solution to a significant extent. To evaluate the immune activity of LTB-GIT, an ELISA assay was performed. The ELISA results showed that the OD 450nm value of the LTB-GIT group was not significantly different from that of the LTB group, but was obviously higher than that of the BSA protein group (Fig. 2b) , while in addition the OD 450nm value of the LTB-GIT group was not significantly changed compared with that of the GIT protein group, although it was markedly higher than that of the BSA protein group (Fig. 2c) . Therefore, our results show that LTB-GIT can react with serum from mice immunized with LTB and GIT, respectively. This result indicates that LTB-GIT can trigger an immune response in vitro and also that LTB does not obstruct GIT immunogenicity. Thus, LTB might be a suitable intra-molecular adjuvant for GIT. Altogether, the successful preparation of LTB-GIT provided a solid base for subsequent immunization and challenge work.
Double adjuvants improved antigen-specific CD4 + T cell immune responses
The CD4 + T cell response may represent a cell-mediated immune response. To characterize the antigen-induced T cells response, we detected CD4 + T cells immune activation induced by LTB-GIT or LTB-GIT plus CpG. Because the cellular immune response may be associated with the ability to produce different cytokines at the single-cell level [28] , the antigen-induced CD4 + T cell responses were analysed by ICS. With the background controls subtracted, the production of each of the four cytokines IFN-g, IL-2, IL-4 and IL-10 generated by antigen-specific CD4 + T cells from the immunized mice is shown in Fig. 3 . Compared to the GITgroup, the mice immunized with LTB-GIT or GIT plus CpG generated significantly higher antigen-specific CD4 + T cell responses for IFN-g, IL-2, and IL-10, but IL-4 was only slightly increased. Notably, the mice vaccinated with GIT plus double adjuvants (LTB and CpG) exhibited the strongest antigen-specific CD4 + T cell responses for FN-g, IL-2, IL-4 and IL-10 among all of the groups (Fig. 3) . These results show that the double adjuvants improved the antigen-specific CD4 + T cell responses and more markedly enhanced the GIT-induced immune responses compared to the single adjuvant in mice.
Generally, IFN-g and IL-2 are mainly produced by Th1 cells and may improve CD8 + T cell-mediated immune responses, and IL-4 and IL-10 are mainly secreted by Th2 cells and promote B cell-mediated immune response. Therefore, from the above data, the double adjuvants, LTB and CpG, can act in synergy to enhance the activation of Th1 and Th2 cells, and then further strengthen the T-cell-mediated immune responses and enhance the humoral immune responses.
Double adjuvants enhanced GIT-induced humoral immune responses
Prior to studying the role of the double adjuvants LTB and CpG on GIT-induced immune responses in mice, we initially measured the level of antibodies against GIT by ELISA. On day 35 post-immunization, compared to the GIT group, the LTB-GIT group and the GIT plus CpG group induced higher IgG levels (Fig. 4) . Of note, the LTB-GIT plus CpG group induced the highest IgG levels among all groups (Fig. 4) . These results indicate that double adjuvants can obviously improve GIT-induced humoral immune responses in mice.
Double adjuvants promoted GIT-induced protective immune responses
To further confirm whether the LTB-GIT plus CpG was able to induce effective immuno-protection in mice, we performed a challenge assay by using a clinical Streptococcus isolate, S. dysgalactiae strain LS0312 and S. aureus strain Newman. As shown in Fig. 5a , on day 14 following S. dysgalactiae challenge, the survival rate of mice immunized with LTB-GIT plus CpG, LTB-GIT and GIT plus CpG reached a protection of 70, 40 and 50 %, respectively, while the mice from the PBS group were all dead. Following S. aureus strain Newman infection, as shown in Fig. 5b , the mice immunized with LTB-GIT plus CpG exhibited the highest survival rate (60 %) among all of the groups. The LTB-GIT and GIT plus CpG groups displayed survival rates of 40 and 50 %, respectively, both of which were higher than that of the single GIT group. These data revealed that double adjuvants not only significantly enhanced the immuno-protection efficacy of GIT, but also induced a cross-immuno-protection in mice. Thus, LTB-GIT plus CpG may be selected as a potential vaccine candidate against S. aureus and Streptococcus infection.
DISCUSSION
In this study, we successfully obtained LTB-GIT fusion protein and ELISA results showed that LTB-GIT exhibited strong immune activity. Importantly, LTB, as an intramolecular adjuvant, did not impair the immunocompetence of GIT. Furthermore, the double adjuvants LTB and CpG were able to strengthen the GIT immunogenicity in mice significantly.
S. aureus and streptococcal species are ubiquitous pathogens and have been considered to be a major cause of nosocomial infections worldwide that are associated with high death rates in both humans and animals [29] [30] [31] . For example, cow mastitis, a very common infectious and costly disease in dairy cattle, is often caused by mixed infection of S. aureus and streptococcal species [32, 33] . However, to date, an effective vaccine candidate to prevent their mixed infection is still lacking.
Our previous work showed that GIT protein plus Freund's adjuvant presented strong cross-immuno-protection against S. aureus, Streptococcus agalactiae, S. dysgalactiae and Streptococcus uberis, and was thus considered to be a potential vaccine candidate [8] . However, the side-effects of Freund's adjuvant, such as swelling, the formation of the epithelioid macrophage granuloma at the site of injection and local ulceration, restricts its utilization in vaccine Fig. 4 . Serum antibody response in mice immunized with PBS, GIT, GIT plus CpG, LTB-GIT and LTB-GIT plus CpG. Sera were collected from the mice on 14 days after final vaccination, and the levels of antibody against GIT in mice serum were detected by ELISA. The data are shown as the mean±SD (n=3).
development [34] . Thus, here, we applied a LTB and CpG combination instead of Freund's adjuvant to enhance GIT immunogenicity.
LTB of E. coli exerts multiple biological functions. For instance, it may trigger immuno-modulatory activities via binding the GM1-ganglioside molecule on the surface of mammalian cells [21, 35] . It can also induce elevation of both Th1-and Th2-type cytokines [36] , promote the expression of MHC II, CD25, CD40 and B7, as well as intracellular cell adhesion molecule-1 (ICAM-1) [20] on the Bcell surface, improve the antigen presentation of B cells [37, 38] , dendritic cells [39] and macrophages [40] , and increase antibody responses to co-administered protein antigens [41] . Therefore, LTB has attracted considerable attention due to its exceptionally potent adjuvant activity. In addition, CpG via TLR9 induces the Th1-cell-mediated and B-cellmediated immune response by stimulating the production of pro-inflammatory cytokines [42] . Based on these data, we speculated that the combination of LTB and CpG adjuvant might maximize GIT immunogenicity and provide a novel strategy for enhancing the immuno-protection effects of vaccine candidates.
The ICS results showed that LTB-GIT plus CpG adjuvant significantly enhanced the GIT-specific CD4 + T cell responses for IL-2, IL-4, IL-10 and IFN-g compared to GIT plus CpG or LTB-GIT. In addition, our novel strategy promoted B cell production of higher IgG levels against GIT in mice, suggesting that the double adjuvants were also able to induce stronger humoral immunity against GIT compared to CpG or LTB alone. Intriguingly, the IgG levels produced by the LTB-GIT group were significantly higher than those for the GIT plus CpG group. This was probably because LTB improved the ability of B cells to capture, process and present GIT antigens via binding to GM1 on B cell surfaces. Most importantly, the challenge data showed that LTB-GIT plus CpG obviously enhanced the GIT-induced immunoprotection rate against S. aureus and S. dysgalactiae. Taken together, our data demonstrated that a combination of LTB and CpG adjuvant is able to significantly increase T-and Bcell-mediated immune responses against GIT. However, to slow antigen release into the microenvironment and extend antigen-induced immune responses in vivo, aluminium adjuvant needs to be added to LTB-GIT and CpG complexes, which will be considered in our future research. In addition, in this study, we only selected S. dysgalactiae strain LS0312 and S. aureus strain Newman as the challenge strains, and other S. aureus and streptococcal strains should be used to further investigate the immuno-protection effects induced by the LTB-GIT plus CpG complex in the future.
Conclusions
Taken together, our data showed that the double adjuvants LTB and CpG exhibited stronger immune modulation effects and significantly enhanced GIT-induced immunoprotective responses, which may serve as an important basis for novel vaccine development to prevent S. aureus and streptococcal species infection. 
